NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATE
晚期前列腺中的中性内肽酶失活
基本信息
- 批准号:2896750
- 负责人:
- 金额:$ 29.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-06-01 至 2002-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Neutral endopeptidase 24.11 (NEP) is a cell-surface peptidase expressed
by prostatic epithelial cells which cleaves and inactivates
neuropeptides implicated in the growth of androgen-independent prostate
cancer (PC). We show that NEP expression and catalytic activity are
lost in vitro in androgen-independent but not androgen-dependent PC cell
lines. In vivo, NEP protein expression is commonly decreased in cancer
cells of metastatic PC specimens from patients with androgen-independent
but not androgen-dependent PC. Overexpression of NEP in androgen-
independent PC cells or incubation with recombinant NEP inhibits PC cell
growth. Furthermore, in androgen-dependent PC cells, expression of NEP
is transcriptionally regulated by androgen and decreases with androgen-
withdrawal. Consequently, PC cells which survive androgen-withdrawal
can emerge with reduced NEP. These data suggest that decreased NEP
expression, common in androgen-independent PCS, is facilitated by the
elimination of androgens, and that NEP loss plays an important role in
the development of androgen-independent PC by allowing PC cells to use
mitogenic neuropeptides as an alternate source to androgen to stimulate
cell proliferation. To thoroughly define the involvement of NEP on
androgen-independent PC cells, our specific aims are (1) to explore the
mechanism by which NEP inhibits cell growth; (2) to establish that the
androgen response element (ARE) in the 3' end of the NEP gene is a
functional ARE which enhances transcription of the NEP gene; and (3) to
assess the antitumor effects of NEP in an animal model of prostate
cancer by establishing that recombinant NEP can inhibit the
tumorigenicity of androgen-independent PC cells in an orthotopic model
of PC, and to establish that overexpression of NEP in androgen-
independent PC cells inhibits the tumorigenicity of androgen-independent
PC cells. These studies leading to a better understanding of the
involvement of NEP in the development and progression of androgen-
independent PC may ultimately provide support for novel approaches for
the treatment of advanced PC.
中性内肽酶24.11(NEP)是一种细胞表面肽酶,
前列腺上皮细胞分裂并灭活
与雄激素非依赖性前列腺生长有关的神经肽
癌症(PC)。 我们发现,NEP的表达和催化活性,
在雄激素非依赖性PC细胞而非雄激素依赖性PC细胞中的体外丢失
线 在体内,NEP蛋白表达通常在癌症中降低,
来自雄激素非依赖性前列腺癌患者的转移性PC标本的细胞
而不是雄激素依赖性PC。 NEP在雄激素中的过度表达-
独立的PC细胞或与重组NEP孵育抑制PC细胞
增长 此外,在雄激素依赖性PC细胞中,NEP的表达
在转录上受雄激素调节,并随雄激素减少-
戒断 因此,雄激素戒断后存活的PC细胞
可以减少NEP。 这些数据表明,
在雄激素非依赖性PCS中常见的表达,
雄激素的消除,NEP的损失在
雄激素非依赖性PC的发展,允许PC细胞使用
促有丝分裂神经肽作为雄激素的替代来源,
细胞增殖 为了彻底界定NEP的参与,
雄激素非依赖性PC细胞,我们的具体目标是(1)探索
NEP抑制细胞生长的机制;(2)建立NEP抑制细胞生长的机制。
NEP基因3'端的雄激素反应元件(ARE)是一个雄激素受体,
增强NEP基因转录的功能性ARE;和(3)
评估NEP在前列腺动物模型中的抗肿瘤作用
通过建立重组NEP可以抑制
雄激素非依赖性PC细胞原位模型的致瘤性
的PC,并建立NEP在雄激素-
非雄激素依赖性PC细胞的致瘤性
PC细胞。 这些研究有助于更好地了解
NEP参与雄激素的发展和进展-
独立PC最终可能为新方法提供支持,
晚期PC的治疗
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M. Nanus其他文献
149: Lentiviral Vector Neutral Endopeptidase Gene Transfer Suppresses Prostate Cancer Tumor Growth
- DOI:
10.1016/s0022-5347(18)30414-2 - 发表时间:
2007-04-01 - 期刊:
- 影响因子:
- 作者:
Akio Horiguchi;Ruoqian Shen;Rang Zheng;Oscar B. Goodman;Hanjun Guan;Louis B. Hersh;David M. Nanus - 通讯作者:
David M. Nanus
Novel targets in altered tumour metabolism in kidney cancer
肾癌中肿瘤代谢改变的新靶点
- DOI:
10.1038/nrurol.2015.168 - 发表时间:
2015-07-28 - 期刊:
- 影响因子:14.600
- 作者:
Denise R. Minton;David M. Nanus - 通讯作者:
David M. Nanus
Infrequent <em>ras</em> Oncogene Point Mutations in Renal Cell Carcinoma
- DOI:
10.1016/s0022-5347(17)39905-6 - 发表时间:
1990-01-01 - 期刊:
- 影响因子:0.4
- 作者:
David M. Nanus;Iris R. Mentle;Robert J. Motzer;Neil H. Bander;Anthony P. Albino - 通讯作者:
Anthony P. Albino
608: Neutral Endopeptidase Targeted to Prostate Cancer Cells Via Fusion with an Anti-Prostate Specific Membrane Antigen Monoclonal Antffiody
- DOI:
10.1016/s0022-5347(18)37870-4 - 发表时间:
2004-04-01 - 期刊:
- 影响因子:
- 作者:
David Y.T. Chen;Ruoqian Shen;Daniel Navarro;Neil H. Bander;Michael C. Gong;Michel Sadelain;David M. Nanus - 通讯作者:
David M. Nanus
MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (<sup>177</sup>LU-J591) FOR MCRPC
- DOI:
10.1016/j.juro.2016.02.453 - 发表时间:
2016-04-01 - 期刊:
- 影响因子:
- 作者:
Jaspreet S. Batra;Beerinder Karir;Kavya Pinto-Chengot;Yuliya S. Jhanwar;Shankar Vallabhajosula;Paul J. Christos;Gillian Hodes;Linda Lam;Ana Molina;Himisha Beltran;Stanley J. Goldsmith;David M. Nanus;Neil H. Bander;Scott T. Tagawa - 通讯作者:
Scott T. Tagawa
David M. Nanus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M. Nanus', 18)}}的其他基金
PHASE II TRIAL OF 177LU-J591 IN METASTATIC, ANDROGEN-INDEPENDENT PROSTATE CANCER
177LU-J591 治疗不依赖雄激素的转移性前列腺癌的 II 期试验
- 批准号:
7604180 - 财政年份:2007
- 资助金额:
$ 29.79万 - 项目类别:
PHASE I TRIAL OF ATRA-IV & DEPAKOTE IN PTS W/ADVANCED SOLID TUMOR MALIGNANCIES
ATRA-IV 的 I 期试验
- 批准号:
7378405 - 财政年份:2006
- 资助金额:
$ 29.79万 - 项目类别:
PHASE I TRIAL OF ATRA-IV & DEPAKOTE IN PTS W/ADVANCED SOLID TUMOR MALIGNANCIES
ATRA-IV 的 I 期试验
- 批准号:
7200405 - 财政年份:2005
- 资助金额:
$ 29.79万 - 项目类别:
Phase I 111-Indium radiolabeled mAb huJ591/ metastatic solid tumors
I 期 111-铟放射性标记单克隆抗体 huJ591/转移性实体瘤
- 批准号:
7040610 - 财政年份:2004
- 资助金额:
$ 29.79万 - 项目类别:
Chemoprevention of Prostate Cancer with Finasteride
非那雄胺化学预防前列腺癌
- 批准号:
7040595 - 财政年份:2004
- 资助金额:
$ 29.79万 - 项目类别:
Modulation of retinoic acid action in renal cancer
视黄酸在肾癌中作用的调节
- 批准号:
6522891 - 财政年份:2001
- 资助金额:
$ 29.79万 - 项目类别:
Modulation of retinoic acid action in renal cancer
视黄酸在肾癌中作用的调节
- 批准号:
6642797 - 财政年份:2001
- 资助金额:
$ 29.79万 - 项目类别:
Modulation of retinoic acid action in renal cancer
视黄酸在肾癌中作用的调节
- 批准号:
6804992 - 财政年份:2001
- 资助金额:
$ 29.79万 - 项目类别:
Modulation of retinoic acid action in renal cancer
视黄酸在肾癌中作用的调节
- 批准号:
6923660 - 财政年份:2001
- 资助金额:
$ 29.79万 - 项目类别:
Modulation of retinoic acid action in renal cancer
视黄酸在肾癌中作用的调节
- 批准号:
6369218 - 财政年份:2001
- 资助金额:
$ 29.79万 - 项目类别:
相似海外基金
Abnormalities in androgens and ovarian markers in reproductive-age racially and ethnically diverse women in a prospective longitudinal cohort
前瞻性纵向队列中不同种族和民族的育龄女性雄激素和卵巢标志物的异常
- 批准号:
10930196 - 财政年份:2023
- 资助金额:
$ 29.79万 - 项目类别:
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
多囊卵巢综合征中的非酒精性脂肪肝 (NAFLD):雄激素在肝损伤和 NAFLD 进展中的作用
- 批准号:
10735807 - 财政年份:2023
- 资助金额:
$ 29.79万 - 项目类别:
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
阐明细胞识别和响应不同水平雄激素的机制
- 批准号:
10418461 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别:
Sexual Differentiation of the Brain and Behaviour: Central and Peripheral Targets of Androgens
大脑和行为的性别分化:雄激素的中枢和外周目标
- 批准号:
RGPIN-2019-04999 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别:
Discovery Grants Program - Individual
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
- 批准号:
10570208 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
- 批准号:
10688086 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
- 批准号:
10355174 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别:
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome
使用新型 11-含氧雄激素提高多囊卵巢综合征的诊断准确性和治疗效果
- 批准号:
10431620 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别:
Defining the impact of androgens on uterine immune cell function during endometrial tissue repair
确定子宫内膜组织修复过程中雄激素对子宫免疫细胞功能的影响
- 批准号:
2744296 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别:
Studentship
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
- 批准号:
10525097 - 财政年份:2022
- 资助金额:
$ 29.79万 - 项目类别: